Glenmark Pharmaceuticals seeks licensing deal for ISB 2001 drug candidate, plans growth with semaglutide in India.

The author has a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 months, representing significant upside from its ...

The fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious ...

Qure divested for $25M, advanced AMT-130 with FDA approvals, and building infrastructure. A strong balance sheet backs ...

The FDA granted rare pediatric disease designation for OCU410ST, a gene therapy designed to treat ABCA4-associated ...

POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by ...

Recursion Pharmaceuticals RXRX and Schrodinger SDGR are pioneering the use of artificial intelligence (AI) in drug discovery ...

Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators. The biotechnology said Tuesday that the Food and Drug Administration granted the designation ...

The London-based clinical stage biopharmaceutical company targeting diseases said the FDA has granted orphan drug designation to its POLB 001 therapy as an oral preventative treatment for T-cell ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 26, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

The "One Big Beautiful Bill Act" includes negotiation exemptions for orphan drugs approved to treat more than one rare ...